A combination incorporating the antibody–drug conjugate belantamab mafodotin significantly improves the outcomes of people with relapsed or refractory multiple myeloma.
The ESOPEC trial supports the use of perioperative chemotherapy over neoadjuvant chemoradiotherapy in patients with resectable esophageal adenocarcinoma.
Prof. Axel Merseburger shares his GU cancer highlights, such as the MAST trial of metformin in prostate cancer, the SURE-01/02 trial in bladder cancer, and more.
Prof. Sanjay Popat takes us through the key lung cancer studies presented at the conference, including the LAURA and CROWN trials in NSCLC and ADRIATIC in SCLC.
Treatment with the PD-1 inhibitor dostarlimab produces a durable relapse-free response in locally advanced rectal cancer with mismatch repair deficiencies.
Patients with limited-stage SCLC and no progression after chemoradiation derive a significant survival benefit from the use of consolidation durvalumab.
NADINA trial results support the use of neoadjuvant nivolumab plus ipilimumab, followed by response-driven adjuvant therapy, in patients with stage III melanoma.
A liver transplant combined with chemotherapy significantly improves survival in patients with colorectal liver metastases compared with chemotherapy alone.
Trastuzumab deruxtecan leads to clinically significant improvements in overall and progression-free survival versus trastuzumab emtansine in women with metastatic breast cancer.
Treatment with adagrasib leads to clinically meaningful improvement in progression-free survival compared with docetaxel in patients with previously treated KRAS G12C-mutated NSCLC.
Thermal ablation for small colorectal liver metastases is noninferior to surgery, and could reduce the number of complications and shorten hospital stays.
ADCs are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.
Prof. Marion Subklewe takes us through the latest evidence, highlighting the impact of antibiotics, nutrition, and dietary supplements, and discusses how to devise interventions to improve patient outcomes.
Keep your HemOnc knowledge up to date with 45 clinical cases written by renowned experts, featuring knowledge-check questions to support your learning.
